Tempus AI's diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200. Read why TEM ...

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M ...

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...

Tempus AI (NASDAQ:TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly ...

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year strategic collaboration ...

Several near-term factors appear to be weighing on investor confidence in Tempus AI TEM, even as the company remains strategically well positioned over the long term. The company’s Data and Services ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, positions data and AI as central to building a more personalized, scalable healthcare experience, where every customer ...

The region’s hub of diagnostics and testing firms saw a slight increase in employment for the first time in four years, ...

FirmTech, Inc., a sexual health and wellness wearable company focused on data-driven AI innovation, today announced its ...

Wood’s purchase comes as NFLX has already dropped 9% in the new year. ・The Warner Bros. deal and concerns around 2026 ...